Hims & Hers Health Inc. secures distribution agreement with Eli Lilly for weight‑loss therapies

Hims & Hers Health Inc. (NASDAQ: HIMS) announced that it has entered into a partnership with Eli Lilly & Co. (NYSE: LLY) under which the telehealth company will obtain a legitimate, FDA‑approved supply line for the obesity drugs Zepbound and Foundayo. The agreement allows Hims & Hers to sell these medications directly through its multi‑specialty platform, bypassing the regulatory complications that have previously affected the company’s GLP‑1‑based offerings.

Key terms of the partnership

  • Eli Lilly will supply the two branded weight‑loss products to Hims & Hers, ensuring compliance with FDA distribution requirements.
  • The arrangement gives Hims & Hers a stable, regulated channel for the sale of obesity therapeutics, which had been a source of uncertainty for investors.
  • The deal does not change Hims & Hers’ existing business model; it simply augments the company’s product portfolio with proven, commercially available drugs.

Market impact

  • Following the announcement, Hims & Hers shares gained momentum as part of a broader rebound in U.S. equities after a significant sell‑off on Thursday.
  • The recovery was particularly noticeable in technology‑related stocks, and the telehealth firm’s inclusion in the rally reflected investor confidence in the new partnership.
  • Analysts noted that the agreement removes exposure to the regulatory minefield associated with compounded GLP‑1 therapies and provides a clearer growth trajectory for the company.

Context for investors

  • Current price: $26.00 (close 2026‑11‑05).
  • 52‑week range: $13.74 – $42.70, indicating recent volatility.
  • Market capitalization: $5.61 billion.
  • Price‑earnings ratio: –38.29, reflecting the company’s negative earnings base at present.

The partnership is expected to strengthen Hims & Hers’ position in the weight‑loss market and offer a more reliable revenue stream, potentially easing margin pressures that have been highlighted in the company’s Q3 2026 outlook.